These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1779259)

  • 21. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clarithromycin versus cefaclor in lower respiratory tract infections. The Canadian Bronchitis Study Group.
    Fong IW; Laforge J; Dubois J; Small D; Grossman R; Zakhari R
    Clin Invest Med; 1995 Apr; 18(2):131-8. PubMed ID: 7788958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections.
    Kammer RB; Ress R
    Diagn Microbiol Infect Dis; 1991; 14(1):101-5. PubMed ID: 2013204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Swedish Study Group. A randomized multicenter trial to compare the influence of cefaclor and amoxycillin on the colonization resistance of the digestive tract in patients with lower respiratory tract infection.
    Infection; 1991; 19(4):208-15. PubMed ID: 1917031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2005)].
    Goto H; Takeda H; Kawai S; Watanabe S; Okazaki M; Shimada K; Nakano K; Yokouchi H; Mori T; Igari J; Oguri T; Yamamoto M; Kudo K; Kobayashi N; Tanaka T; Yoshimura K; Kawabata M; Nakamori Y; Sumitomo M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Aoki N; Honma Y; Suzuki Y; Karasawa Y; Oka M; Kobashi Y; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Oikawa S
    Jpn J Antibiot; 2008 Aug; 61(4):209-40. PubMed ID: 19024644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Infections of the lower respiratory tract in general practice].
    Cazzola M
    Infection; 1987; 15 Suppl 3():S113-9. PubMed ID: 3497107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral cefaclor for treatment of bronchitis--a comparative double-blind study versus amoxycillin.
    Beumer HM; Veldkamp J
    Int J Clin Pharmacol Ther Toxicol; 1982 Mar; 20(3):113-7. PubMed ID: 7068283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind comparison of the effects of cefaclor and amoxycillin on respiratory tract and oropharyngeal flora and clinical response in acute exacerbations of bronchitis.
    Trigg CJ; Wilks M; Herdman MJ; Clague JE; Tabaqchali S; Davies RJ
    Respir Med; 1991 Jul; 85(4):301-8. PubMed ID: 1947367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerance of erythromycin acistrate in the treatment of acute exacerbations of chronic bronchitis in the elderly.
    Forsén KO; Wikberg R; Lehtonen L
    Chemotherapy; 1993; 39(6):443-52. PubMed ID: 8222874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2003)].
    Goto H; Takeda H; Kawai S; Nakadate T; Shimada K; Nakano K; Suwabe A; Yokouchi H; Okada S; Ashino Y; Ikemoto H; Gejyo F; Igari J; Okada M; Oguri T; Aoki N; Mori T; Yamamoto M; Kitamura N; Inoue H; Suzuki Y; Karasawa Y; Tosaka M; Kudo K; Kobayashi N; Kohno S; Tanaka T; Hirakata Y; Kondo A; Matsuda J; Nakano M; Sumitomo M; Nasu M; Niki Y; Hiramatsu K; Suga M; Suzuki Y
    Jpn J Antibiot; 2005 Jun; 58(3):326-58. PubMed ID: 16161758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zeckel ML; Jacobson KD; Guerra FJ; Therasse DG; Farlow D
    Clin Ther; 1992; 14(2):214-29. PubMed ID: 1611645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms.
    Cole P
    Clin Ther; 1997; 19(4):617-25; discussion 603. PubMed ID: 9377607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical examination of S 6472 (sustained release preparations of cefaclor on chronic respiratory tract infection].
    Hayashi I; Ohnuma K
    Jpn J Antibiot; 1988 Sep; 41(9):1313-8. PubMed ID: 3241330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapy of chronic recurrent respiratory tract infections].
    Nagatake T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Mar; 27(3):289-92. PubMed ID: 2615085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract]   [Full Text] [Related]  

  • 37. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
    Blondeau JM; Vaughan D; Laskowski R; Borsos S;
    Int J Antimicrob Agents; 2001 Jun; 17(6):457-64. PubMed ID: 11397615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
    Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of experience with ofloxacin in respiratory tract infection.
    Ball P
    Scand J Infect Dis Suppl; 1990; 68():56-63. PubMed ID: 2218424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Branhamella catarrhalis as an indirect pathogen.
    Wardle JK
    Drugs; 1986; 31 Suppl 3():93-6. PubMed ID: 3732085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.